newsfilter
← Latest News
PR Newswire·

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

ABBVQTTBHCWBNKTRLLYINCYPFE
  • The global alopecia areata treatment market is projected to grow significantly by 2036, driven by rising prevalence & increased awareness.
  • The United States holds the largest market share compared to EU4 (Germany, France, Italy, Spain), the UK, & Japan.
  • In 2025, the total diagnosed prevalent cases of alopecia areata in the 7MM (US, EU4, UK, Japan) reached 1.7 million.
  • The US accounted for approximately 620,000 diagnosed cases in 2024, representing nearly 35% of the 7MM total.
  • Emerging therapies poised to reshape the market include RINVOQ, Bempikibart, Coacillium, ALM 223, Amlitelimab, HCW9302, ALY-101, DR-01, & Rezpegaldesleukin.
  • Current approved treatments include JAK inhibitors OLUMIANT, LITFULO, & LEQSELVI, though unmet needs for durable & complete disease control persist.
  • New therapeutic classes such as OX40L & IL-2 inhibitors are being developed to target the root causes of the autoimmune condition.
  • Key market players developing new treatments include AbbVie, Q32 Bio, Legacy Healthcare, Almirall, Sanofi, HCW Biologics, ALYS Pharmaceuticals, Dren Bio, & Nektar Therapeutics.
  • Recent developments include Nektar Therapeutics receiving FDA Fast Track status for rezpegaldesleukin in July 2025 & AbbVie reporting positive Phase 3 results for RINVOQ in alopecia areata.
  • The report covers epidemiological segmentation including prevalent cases, diagnosed cases, gender-specific data, age onset, & severity levels from 2022 to 2036.
  • The study period for the market analysis & forecast is 2022–2036, covering the 7MM leading markets.
  • Existing treatment options include corticosteroids, immunosuppressants, immunomodulators, topical sensitizers, & minoxidil, often used in combination with supportive care.